RISK WATCHReuters • 52m ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
Why PRAX Stock advanced +1.10% Today — RQD Quant Desk Flash
$288.62 +1.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Praxis Precision Medicines Inc. (PRAX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $8.06B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRAX)Realized 20D OHLCV Swing Band: ±9.6%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PRAX Stock advanced +1.10% Today — RQD Quant Desk Flash
Praxis Precision Medicines Inc. (PRAX) advanced +1.10% to $288.62, trading at 56% of its 52-week range ($154.45 – $392.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 56% of its 52-week range ($154.45 – $392.7) with RSI-14 at 56.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.6% around $288.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live PRAX Headlines & Catalysts
MARKET WIREReuters • 2h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 2h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 3h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 3h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 4h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
MARKET WIREReuters • 5h ago
Pope Leo says he hopes Oleshky truce could spur Ukraine-Russia peace efforts - ReutersPope Leo says he hopes Oleshky truce could spur Ukraine-Russia peace efforts Reuters
MARKET WIREReuters • 9h ago
Xiaomi's October EV deliveries top 50,000, hit 2026 monthly high - ReutersXiaomi's October EV deliveries top 50,000, hit 2026 monthly high Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRAX)
- ✓Walkthrough of PRAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PRAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.51%📐 HORIZONTAL RANGE
2026-11-01O $285.5H $288.6L $285.5C $288.6VOL 508.6K
RES: $415.3SUP: $224.5SMA50: $299.5SMA200: $314.8
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PRAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.5%/yr Implied 5Y Growth
vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PRAX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PRAX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRAX)
Health Care Rank #155 of 188
⚔️ ABVX vs PRAX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PRAX vs. ABVX, KNSA, ALKS, ARWR)
Industry: Biotechnology: Pharmaceutical Preparations (64 Tracked Issuers)Across 188 tracked Health Care securities in the Roarable RQD universe, Praxis Precision Medicines Inc. (PRAX) ranks #155 by composite RQD confidence (48/100, grade D) and #126 by equity capitalization ($8.06B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while ALKS leads on capital efficiency and profitability with 14.0% ROIC and 86.7% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with PRAX at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRAX
ACTIVE
Praxis Precision Medicines Inc. | D | 48/100 | — | — | -35.0% | +1.10% | $8.06B | Benchmark Subject |
| ABVX Abivax SA | D+ | 54/100 | 32.8x | — | 9.9% | -0.87% | $7.77B | /abvx-vs-prax → |
| KNSA Kiniksa Pharmaceuticals International plc (Class A) | B- | 71/100 | 129.9x | 88.5% | 9.9% | +2.50% | $7.67B | /knsa-vs-prax → |
| ALKS Alkermes plc | B+ | 79/100 | 31.5x | 86.7% | 14.0% | +0.27% | $7.61B | /alks-vs-prax → |
| ARWR Arrowhead Pharmaceuticals Inc. | C- | 59/100 | — | — | 11.1% | +0.47% | $8.54B | /arwr-vs-prax → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001689548In its most recent audited fiscal period (FY2025, filed 2025-12-31), Praxis Precision Medicines Inc. (PRAX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $8.6M , and -100.0% cumulative change since FY2023) , GAAP net income of -$303.0M, operating cash flow of -$249.1M, and free cash flow of -$249.1M (-89.1% YoY). On the balance sheet, PRAX closed FY2025 with $937.9M in total assets against $26.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$303.0M | -$249.1M | -$249.1M | $937.9M | $26.9M |
| FY2024 (FY) | 2024-12-31 | $8.6M | -$183.0M | -$131.8M | -$131.8M | $483.1M | $16.9M |
| FY2023 (FY) | 2023-12-31 | $2.4M | -$123.0M | -$111.1M | -$111.2M | $4.43B | $1.04B |
3. PRAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Praxis Precision Medicines Inc. (NASDAQ: PRAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $288.62 (+1.10% 1D, market cap $8.06B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 188 tracked Health Care issuers, PRAX ranks #155 in composite RQD confidence.
How does PRAX compare to ABVX and KNSA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRAX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.77B) and KNSA (Kiniksa Pharmaceuticals International plc (Class A)) posts a B- grade (71/100 RQD, P/E 129.9x, ROIC 9.9%, cap $7.67B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while ALKS leads on capital efficiency (14.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PRAX?
Per PRAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001689548), Praxis Precision Medicines Inc. generated $0 in revenue (-100.0% YoY), -$303.0M in net income, and -$249.1M in free cash flow against $937.9M in total assets and $26.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PRAX trading relative to its 50-day, 200-day, and 52-week technical levels?
PRAX last traded at $288.62 (+1.10% on volume of 508,597 shares), positioning the stock -3.65% below its 50-day simple moving average ($299.54) and -8.31% below its 200-day simple moving average ($314.79). Across its 52-week range of $154.45 to $392.70, PRAX sits at the 56.3% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.6% ($260.91 to $316.33).
PRAX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PRAX stock moving today?
Why PRAX Stock advanced +1.10% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.